[an error occurred while processing this directive] | [an error occurred while processing this directive]
Research progress on radiotherapy combined with PD-1/PD-L1 inhibitors in the treatment of breast cancer
Jiang Jie1,2, Huang Wei2
1Weifang Medical University, Weifang 261053, China; 2Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Ji'nan 250117, China
Abstract Radiotherapy has been proven to enhance tumor-specific immune response and provide targets for immune drugs. Immune checkpoint inhibitors represented by PD-1/PD-L1 combined with radiotherapy can enhance anti-tumor activity and exert abscopal effect. In this article, research progress on the basic study and clinical trials and challenges of radiotherapy combined with PD-1/PD-L1 inhibitors in the treatment of breast cancer were reviewed.
Jiang Jie,Huang Wei. Research progress on radiotherapy combined with PD-1/PD-L1 inhibitors in the treatment of breast cancer[J]. Chinese Journal of Radiation Oncology, 2021, 30(4): 424-428.
Jiang Jie,Huang Wei. Research progress on radiotherapy combined with PD-1/PD-L1 inhibitors in the treatment of breast cancer[J]. Chinese Journal of Radiation Oncology, 2021, 30(4): 424-428.
[1] Monneur A, GonçalvesA, Bertucci F. PD-L1 expression and PD-1/PD-L1 inhibitors in breast cancer[J]. Bull Cancer, 2018, 105(3):263-274. DOI:10.1016/j.bulcan.2017.11.012. [2] Gong X, Li X, Jiang T, et al. Combined radiotherapy and anti-PD-L1 antibody synergistically enhances antitumor effect in non-small cell lung cancer[J]. J Thorac Oncol, 2017, 12(7):1085-1097. DOI:10.1016/j.jtho.2017.04.014. [3] Bertucci F, GonçalvesA. Immunotherapy in breast cancer:the emerging role of PD-1 and PD-L1[J]. Curr Oncol Rep, 2017, 19(10):64. DOI:10.1007/s11912-017-0627-0. [4] Pilones KA, Joseph A, Vatner R, et al. Radiation therapy sensitizes a poorly immunogenic breast cancer to PD-1 blockade[J]. Int J Radiat Oncol Biol Phys, 2014, 90(1):S58-S58. DOI:10.1016/j.ijrobp.2014.05.203. [5] Kang J, Pilones KA, Daviaud C, et al. VISTA blockade immunotherapy in a multi-modal approach to triple negative breast cancer (TNBC) in mice and impact on microbiome[J]. Int J Radiat Oncol Biol Phys, 2019, 105(1):S88-S89. DOI:10.1016/j.ijrobp.2019.06.561. [6] Sharabi AB, Nirschl CJ, Kochel CM, et al. Stereotactic radiation therapy augments antigen-specific PD-1-mediated antitumor immune responses via cross-presentation of tumor antigen[J]. Cancer Immunol Res, 2015, 3(4):345-355. DOI:10.1158/2326-6066. CIR-14-0196. [7] Vanpouille-Box C, Alard A, Aryankalayil MJ, et al. DNA exonuclease trexl regulates radiotherapy-induced tumour immunogenicity[J]. Nat Commun, 2017, 8:15618. DOI:10.1038/ncomms15618. [8] Kwa MJ. Checkpoint inhibitors in triple-negative breast cancer (TNBC):where to go from here[J]. Cancer, 2018, 124(10):2086-2103. DOI:10.1002/cncr.31272. [9] Loi S, Sirtaine N, Piette F, et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase Ⅲ randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy:BIG 02-98[J]. J Clin Oncol, 2013, 31(7):860-867. DOI:10.1200/JCO.2011.41.0902. [10] Ho AY, Barker CA, Arnold BB, et al. A phase 2 clinical trialassessing thethe efficacy and safety of pembrolizumab and radiotherapy in patients with metastatic triple-negative breast cancer[J]. Cancer, 2020, 126(4):850-860. DOI:10.1002/cncr.32599. [11] Voorwerk L, Slagter M, Horlings HM, et al. Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade:the TONIC trial[J]. Nat Med, 2019, 25(6):920-928. DOI:10.1038/s41591-019-0432-4. [12] Maity A, Mick R, Huang AC, et al. A phase I trial of pembrolizumab with hypofractionated radiotherapy in patients with metastatic solid tumours[J]. Br J Cancer, 2018, 119(10):1200-1207. DOI:10.1038/s41416-018-0281-9. [13] Deng L, Liang H, Burnette B, et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice[J]. J Clin Invest, 2014, 124(2):687-695. DOI:10.1172/JCI67313. [14] Dovedi SJ, Adlard AL, Lipowska-Bhalla G, et al. Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade[J]. Cancer Res, 2014, 74(19):5458-5468. DOI:10.1158/0008-5472. CAN-14-1258. [15] Friedman D, Baird JR, Young KH, et al. Programmed cell death-1 blockade enhances response to stereotactic radiation in an orthotopic murine model of hepatocellular carcinoma[J]. Hepatol Res, 2017, 47(7):702-714. DOI:10.1111/hepr.12789. [16] Wang X, Schoenhals JE, Li A, et al. Suppression of type I IFN signaling in tumors mediates resistance to anti PD-1 treatment that can be overcome by radiotherapy[J]. Cancer Res, 2017, 77(4):839-850. DOI:10.1158/0008-5472. CAN-15-3142. [17] Twyman-Saint VC, Rech AJ, Maity A, et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer[J]. Nature, 2015, 520(7547):373-377. DOI:10.1038/nature14292. [18] Aguilera TA, Rafat M, Castellini L, et al. Reprogramming the immunological microenvironment through radiation and targeting Axl[J]. Nat Commun, 2016, 7:13898. DOI:10.1038/ncomms13898. [19] Marciscano AE, Ghasemzadeh A, Nirschl TR, et al. Elective nodal irradiation attenuates the combinatorial efficacy of stereotactic radiation therapy and immunotherapy[J]. Clin Cancer Res, 2018, 24(20):5058-5071. DOI:10.1158/1078-0432. CCR-17-3427. [20] Du S, Zhou L, Alexander GS, et al. PD-1 modulates radiation-induced cardiac toxicity through cytotoxic T lymphocytes[J]. J Thorac Oncol, 2018, 13(4):510-520. DOI:10.1016/j.jtho.2017.12.002. [21] Khunger M, Rakshit S, Pasupuleti V, et al. Incidence of pneumonitis with use of programmed death 1 and programmed death-ligand 1 inhibitors in non-small cell lung cancer:a systematic review and meta-analysis of trials[J]. Chest, 2017, 152(2):271-281. DOI:10.1016/j.chest.2017.04.177. [22] Naidoo J, Wang X, Woo KM, et al. Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy[J]. J Clin Oncol, 2017, 35(7):709-717. DOI:10.1200/JCO.2016.68.2005. [23] McGovern K, Ghaly M, Esposito M, et al. Radiation recall pneumonitis in the setting of immunotherapy and radiation:a focused review[J]. Future Sci OA, 2019, 5(5):FSO378. DOI:10.2144/fsoa-2018-0123. [24] Heskamp S, Wierstra PJ, Molkenboer-Kuenen JDM, et al. PD-L1 microSPECT/CT imaging for longitudinal monitoring of PD-L1 expression in syngeneic and humanized mouse models for cancer[J]. Cancer Immunol Res, 2019, 7(1):150-161. DOI:10.1158/2326-6066. CIR-18-0280. [25] Nanda R, Chow LQ, Dees EC, et al. Pembrolizumab in patients with advanced triple-negative breast cancer:phase Ib keynote-012 study[J]. J Clin Oncol, 2016, 34(21):2460-2467. DOI:10.1200/JCO.2015.64.8931. [26] Rugo HS, Delord JP, Im SA, et al. Safety and antitumor activity of pembrolizumab in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer[J]. Clin Cancer Res, 2018, 24(12):2804-2811. DOI:10.1158/1078-0432. CCR-17-3452. [27] Nowicki TS, Hu-Lieskovan S. Mechanisms of resistance to PD-1 and PD-L1 blockade[J]. Cancer J, 2018, 24(1):47-53. DOI:10.1097/PPO.0000000000000303. [28] Sun T, Zhang W, Li Y, et al. Combination immunotherapy with cytotoxic t-lymphocyte-associated antigen-4 and programmed death protein-1 inhibitors prevents postoperative breast tumor recurrence and metastasis[J]. Mol Cancer Ther, 2020, 19(3):802-811. DOI:10.1158/1535-7163. MCT-19-0495. [29] Zhang J, Bu X, Wang H, et al. Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance[J]. Nature, 2018, 553(7686):91-95. DOI:10.1038/nature25015. [30] Panagi M, Voutouri C, Mpekris F, et al. TGF-β inhibition combined with cytotoxic nanomedicine normalizes triple negative breast cancer microenvironment towards anti-tumor immunity[J]. Theranostics, 2020, 10(4):1910-1922. DOI:10.7150/thno.36936. [31] Dillon PM, Petroni GR, Smolkin ME, et al. A pilot study of the immunogenicity of a 9-peptide breast cancer vaccine plus poly-ICLC in early stage breast cancer[J]. J Immunother Cancer, 2017, 5(1):92. DOI:10.1186/s40425-017-0295-5. [32] Gasparetto C, Gasparetto M, Morse M, et al. Mobilization of dendritic cells from patients with breast cancer into peripheral bloodstem cell leukapheresis samples using Flt-3-Ligand and G-CSF or GM-CSF[J]. Cytokine, 2002, 18(1):8-19. DOI:10.1006/cyto.2002.1009. [33] Poleszczuk J, Luddy K, Chen L, et al. Neoadjuvant radiotherapy of early-stage breast cancer and long-term disease-free survival[J]. Breast Cancer Res, 2017, 19(1):75. DOI:10.1186/s13058-017-0870-1.
2021, Vol. 30 
